`Slayback v. Eye Therapies - IPR2022-00142
`
`
`
`Slayback-Pharma – Connecting the Dots
`
`https://slayback-pharma.com/
`
`nov2021.pdf)
`OUR TEAM (HTTPS://SLAYBACK-PHARMA.COM/OUR-STAFF/ )
`MYOLDMEDS.COM, DRUG TAKE-BACK LOCATOR
`PRODUCTS (HTTPS://SLAYBACK-PHARMA.COM/PRODUCTS/ )
`
`(https://slayback-
`
`LATEST NEWS (HTTPS://WWW.PRNEWSWIRE.COM/NEWS/SLAYBACK-PHARMA-LLC/ )
`
`pharma.com )
`
`CAREERS (HTTPS://SLAYBACK-PHARMA.COM/CAREERS/ )
`
`
`
`CONTACT (HTTPS://SLAYBACK-PHARMA.COM/CONTACT/ )
`(https://www.prnewswire.com/news-releases
`/slayback-appoints-paul-campanelli-to-board-of-
`directors-301236356.html)
``` SLAYBACK APPOINTS PAUL CAMPANELLI TO
`BOARD OF DIRECTORS ``
`
`(https://www.prnewswire.com/news-releases
`/slayback-appoints-dave-picard-as-chief-
`commercial-of�cer-301228712.html)
``` SLAYBACK APPOINTS DAVE PICARD AS CHIEF
`COMMERCIAL OFFICER ``
`
`VIEW DETAIL (HTTPS://WWW.PRNEWSWIRE.COM/NEWS-RELEASES
`/SLAYBACK-APPOINTS-PAUL-CAMPANELLI-TO-BOARD-OF-DIRECTORS-
`
`VIEW DETAIL (HTTPS://WWW.PRNEWSWIRE.COM/NEWS-RELEASES
`/SLAYBACK-APPOINTS-DAVE-PICARD-AS-CHIEF-COMMERCIAL-OFFICER-
`
`(https://www.prnewswire.com/news-releases
`/slayback-pharma-appoints-dr-sumitra-pillai-as-
`head-of-rd-301187282.html)
``` SLAYBACK PHARMA APPOINTS DR SUMITRA
`PILLAI AS HEAD OF RESEARCH AND
`DEVELOPMENT ``
`
`VIEW DETAIL (HTTPS://WWW.PRNEWSWIRE.COM/NEWS-RELEASES
`/SLAYBACK-PHARMA-APPOINTS-DR-SUMITRA-PILLAI-AS-HEAD-OF-
`
`(https://www.prnewswire.com/news-releases
`/slayback-pharma-announces-fda-approval-of-
`merzee-generic-equivalent-of-taytulla-with-
`a-competitive-generic-therapy-cgt-designation-
`301196210.html)
``` SLAYBACK PHARMA ANNOUNCES FDA
`APPROVAL OF MERZEE, GENERIC EQUIVALENT
`OF TAYTULLA WITH A COMPETITIVE GENERIC
`
`
`
`VIEW DETAILS (HTTPS://WWW.PRNEWSWIRE.COM/NEWS-RELEASES
`/SLAYBACK-PHARMA-ANNOUNCES-FDA-APPROVAL-OF-MERZEE-
`GENERIC-EQUIVALENT-OF-TAYTULLA-WITH-A-COMPETITIVE-GENERIC-
`
`Slayback Pharma LLC
`
` (tel:(+1) 609 945 3443) (+1) 609 945 3443 (tel:(+1) 609 945 3443)
`
` (mailto:contact@slayback-pharma.com) contact@slayback-pharma.com (mailto:contact@slayback-
`
`
`
`pharma.com)
`
`2 of 3
`
`8/22/2022, 4:05 PM
`
`Eye Therapies Exhibit 2142, 2 of 3
`Slayback v. Eye Therapies - IPR2022-00142
`
`
`
`Slayback-Pharma – Connecting the Dots
`
`https://slayback-pharma.com/
`
`301 Carnegie Center, Suite 303, Princeton, NJ 08540 (https://www.google.com/maps/place/)
`
`OUR TEAM (HTTPS://SLAYBACK-PHARMA.COM/OUR-STAFF/ )
`
`PRODUCTS (HTTPS://SLAYBACK-PHARMA.COM/PRODUCTS/ )
`
`(https://slayback-
`
`LATEST NEWS (HTTPS://WWW.PRNEWSWIRE.COM/NEWS/SLAYBACK-PHARMA-LLC/ )
`
`pharma.com )
`
`CAREERS (HTTPS://SLAYBACK-PHARMA.COM/CAREERS/ )
`
`
`
`CONTACT (HTTPS://SLAYBACK-PHARMA.COM/CONTACT/ )
`
`Copyright ©2021 all rights reserved
`
`3 of 3
`
`8/22/2022, 4:05 PM
`
`Eye Therapies Exhibit 2142, 3 of 3
`Slayback v. Eye Therapies - IPR2022-00142
`
`